Continuous-time Markov modelling of flexible-dose depression trials.

about

Continuous-time Markov modelling of flexible-dose depression trials.

Item

http://www.wikidata.org/entity/Q43940338

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Continuous-time Markov modelling of flexible-dose depression trials.

@en

Continuous-time Markov modelling of flexible-dose depression trials.

@nl

type

Item

label

Continuous-time Markov modelling of flexible-dose depression trials.

@en

Continuous-time Markov modelling of flexible-dose depression trials.

@nl

prefLabel

Continuous-time Markov modelling of flexible-dose depression trials.

@en

Continuous-time Markov modelling of flexible-dose depression trials.

@nl

P1476

Continuous-time Markov modelling of flexible-dose depression trials.

@en

P2093

Alberto Russu

http://www.w3.org/2001/XMLSchema#string

Eleonora Marostica

http://www.w3.org/2001/XMLSchema#string

Giuseppe De Nicolao

http://www.w3.org/2001/XMLSchema#string

Roberto Gomeni

http://www.w3.org/2001/XMLSchema#string

Stefano Zamuner

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

A joint model for nonlinear longitudinal data with informative dropout.

Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.

Modelling placebo response in depression trials using a longitudinal model with informative dropout.

Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.

Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.

Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: a case study in depression.

Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder.

Bayesian population modeling of phase I dose escalation studies: Gaussian process versus parametric approaches.

P2888

s10928-014-9389-6

P304

625-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-014-9389-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25281421

http://www.w3.org/2001/XMLSchema#string